Formulation and clinical translation of inhalable nanomedicines for the treatment and prevention of pulmonary infectious diseases DOI Creative Commons
Rami Ahmed, Frédéric Tewes, Marique Aucamp

et al.

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Abstract Pulmonary infections caused by bacteria, viruses and fungi are a significant global health issue. Inhalation therapies gaining interest as an effective approach to directly target infected lung sites nanoparticle-based pulmonary delivery systems increasingly investigated for this purpose. In review, we provide overview of common infectious diseases review recent work on the application inhalable formulations diseases, formulation strategies, current research delivering nanomedicines. We also evaluate clinical development status, market landscape, discuss challenges that impede translation propose solutions overcome these obstacles, highlighting promising opportunities future advancements in field. Despite made products reaching market, notable gap persists translational research, with achieving product profile, availability appropriate vivo disease models, scale-up, related questions, likely hindering clinic. Graphical

Language: Английский

Polysaccharide nanoparticles as potential immune adjuvants: Mechanism and function DOI Creative Commons
Yuhong Jiang, Shanshan Qi, Canquan Mao

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Citations

0
Formulation and clinical translation of inhalable nanomedicines for the treatment and prevention of pulmonary infectious diseases DOI Creative Commons
Rami Ahmed, Frédéric Tewes, Marique Aucamp

et al.

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Abstract Pulmonary infections caused by bacteria, viruses and fungi are a significant global health issue. Inhalation therapies gaining interest as an effective approach to directly target infected lung sites nanoparticle-based pulmonary delivery systems increasingly investigated for this purpose. In review, we provide overview of common infectious diseases review recent work on the application inhalable formulations diseases, formulation strategies, current research delivering nanomedicines. We also evaluate clinical development status, market landscape, discuss challenges that impede translation propose solutions overcome these obstacles, highlighting promising opportunities future advancements in field. Despite made products reaching market, notable gap persists translational research, with achieving product profile, availability appropriate vivo disease models, scale-up, related questions, likely hindering clinic. Graphical

Language: Английский

Citations

0